Conditions: Chronic Idiopathic Urticaria
Keywords: Chronic idiopathic urticaria CIU Xolair IGE025 FcεRI IgE
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 40
Healthy volunteers: no

Brief summary:
The study is designed to explore the mode of action for omalizumab therapy in patients with chronic idiopathic urticaria.

Detailed description:

Arms:
arm 1: Patients will receive omalizumab administered subcutaneously every 4 weeks at the study center. arm 2: Placebo administered subcutaneously every 4 weeks at the study center.

Interventions: intervention 1: IGE025 intervention 2: placebo
Intervention descriptions: intervention 1: Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial. intervention 2: Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.

Protocol document: